person · Reporting owner

Rodman David Malcom

Disclosed activity across 2 companies

Tapewire entity: 24112
SEC CIK: 0001672659

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802	Exec Vice President and CMO	January 03, 2017	January 05, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALPINE IMMUNE SCIENCES, INC.

Report date January 03, 2017 · Filed January 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,368	Ending reported balance After 2017-01-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-01-03 · Exercise / conversion · Acquired 18,055 · Balance 18,055 F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Row 2 · 2017-01-04 · Sale · Disposed 6,687 · Balance 11,368 F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	162,501	Reported balance After 2017-01-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-03 · Exercise / conversion · Disposed 18,056 · Balance 162,501 F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.

F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mineralys Therapeutics, Inc.

Report date August 10, 2026 · Filed August 12, 2026

Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	51,384	Ending reported balance After 2026-08-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-10 · Exercise / conversion · Acquired 2,170 · Balance 53,554 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Row 2 · 2026-08-10 · Sale · Disposed 2,170 · Balance 51,384 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2033-02-09	Direct	13,024	Reported balance After 2026-08-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-10 · Exercise / conversion · Disposed 2,170 · Balance 13,024 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 13, 2026 Filed Apr 16, 2026 01:45 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	3,542	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · derivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,417 Underlying: Common Stock · 3,542 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document
April 13, 2026 Filed Apr 16, 2026 01:45 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	6,349	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · derivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,046 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
April 13, 2026 Filed Apr 16, 2026 01:45 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	14,058	$26.54	$373,086.67	Disclosure SEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,140 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.3676 to $26.8400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
April 13, 2026 Filed Apr 16, 2026 01:45 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	4,167	$14.25	$59,379.75	Disclosure SEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
April 13, 2026 Filed Apr 16, 2026 01:45 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	3,542	$10.20	$36,128.40	Disclosure SEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
April 13, 2026 Filed Apr 16, 2026 01:45 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	6,349	$1.08	$6,856.92	Disclosure SEC source: 0001933414-26-000076 · wk-form4_1776303923.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
April 09, 2026 Filed Apr 14, 2026 01:13 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	2,170	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001672659-26-000020 · wk-form4_1776129225.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,706 Underlying: Common Stock · 2,170 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
April 09, 2026 Filed Apr 14, 2026 01:13 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	2,170	$27.38	$59,414.60	Disclosure SEC source: 0001672659-26-000020 · wk-form4_1776129225.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,140 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
April 09, 2026 Filed Apr 14, 2026 01:13 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	2,170	$16.00	$34,720.00	Disclosure SEC source: 0001672659-26-000020 · wk-form4_1776129225.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 17, 2026 Filed Mar 17, 2026 20:51 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	417	$0.00 Strike: $15.44	$0.00	Disclosure SEC source: 0001672659-26-000018 · wk-form4_1773780674.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 417 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
March 17, 2026 Filed Mar 17, 2026 20:51 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	417	$25.65	$10,696.05	Disclosure SEC source: 0001672659-26-000018 · wk-form4_1773780674.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,140 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 17, 2026 Filed Mar 17, 2026 20:51 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	417	$15.44	$6,438.48	Disclosure SEC source: 0001672659-26-000018 · wk-form4_1773780674.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	4,167	$0.00 Strike: $14.25	$0.00	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · derivative · entry 10 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,834 Underlying: Common Stock · 4,167 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	3,542	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · derivative · entry 9 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,959 Underlying: Common Stock · 3,542 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	253	$27.82	$7,038.46	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,140 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	3,079	$27.37	$84,264.53	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,393 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.772 to $27.720. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	10,726	$25.91	$277,922.46	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,472 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.77 to $26.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	4,167	$14.25	$59,379.75	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 13, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	3,542	$10.20	$36,128.40	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 12, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	6,348	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · derivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,395 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
March 12, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	6,348	$27.37	$173,747.93	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.02 to $27.92. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
March 12, 2026 Filed Mar 16, 2026 21:20 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	6,348	$1.08	$6,855.84	Disclosure SEC source: 0001933414-26-000058 · wk-form4_1773696009.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 09, 2026 Filed Mar 10, 2026 21:48 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	2,171	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001672659-26-000015 · wk-form4_1773179312.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,876 Underlying: Common Stock · 2,171 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
March 09, 2026 Filed Mar 10, 2026 21:48 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	2,171	$26.84	$58,269.64	Disclosure SEC source: 0001672659-26-000015 · wk-form4_1773179312.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,489 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
March 09, 2026 Filed Mar 10, 2026 21:48 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	2,171	$16.00	$34,736.00	Disclosure SEC source: 0001672659-26-000015 · wk-form4_1773179312.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 19, 2026 Filed Feb 21, 2026 00:46 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	GrantStock Option · Derivative	51,300	$0.00 Strike: $28.06	$0.00	Disclosure SEC source: 0001933414-26-000038 · wk-form4_1771634813.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,300 Underlying: Common Stock · 51,300 shares Expires 2036-02-19 F2 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant Read SEC document
February 19, 2026 Filed Feb 21, 2026 00:46 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	GrantCommon Stock	38,400	$0.00	$0.00	Disclosure SEC source: 0001933414-26-000038 · wk-form4_1771634813.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,489 F1 · shares: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of the date of grant. Read SEC document
February 17, 2026 Filed Feb 17, 2026 23:56 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	417	$0.00 Strike: $15.44	$0.00	Disclosure SEC source: 0001672659-26-000013 · wk-form4_1771372594.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,417 Underlying: Common Stock · 417 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
February 17, 2026 Filed Feb 17, 2026 23:56 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	417	$27.59	$11,505.03	Disclosure SEC source: 0001672659-26-000013 · wk-form4_1771372594.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,089 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 17, 2026 Filed Feb 17, 2026 23:56 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	417	$15.44	$6,438.48	Disclosure SEC source: 0001672659-26-000013 · wk-form4_1771372594.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	4,166	$0.00 Strike: $14.25	$0.00	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · derivative · entry 11 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,001 Underlying: Common Stock · 4,166 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	3,541	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · derivative · entry 10 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,501 Underlying: Common Stock · 3,541 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F6 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	6,348	$27.58	$175,100.06	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 8 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,089 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.3300 to $28.0000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	4,166	$27.33	$113,856.78	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 7 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	4,166	$14.25	$59,365.50	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	3,541	$27.33	$96,775.53	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 13, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	3,541	$10.20	$36,118.20	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 12, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	6,349	$0.00 Strike: $1.08	$0.00	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · derivative · entry 9 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,743 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F5 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
February 12, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	521	$29.64	$15,441.76	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.5870 to $29.6600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document
February 12, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	5,828	$28.94	$168,634.93	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,958 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.5200 to $29.4200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
February 12, 2026 Filed Feb 14, 2026 00:25 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	6,349	$1.08	$6,856.92	Disclosure SEC source: 0001672659-26-000011 · wk-form4_1771028714.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:58 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	2,171	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001933414-26-000007 · wk-form4_1770854332.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,047 Underlying: Common Stock · 2,171 shares Expires 2033-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:58 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	2,171	$30.21	$65,585.91	Disclosure SEC source: 0001933414-26-000007 · wk-form4_1770854332.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:58 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	2,171	$16.00	$34,736.00	Disclosure SEC source: 0001933414-26-000007 · wk-form4_1770854332.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
January 20, 2026 Filed Jan 21, 2026 01:33 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	416	$0.00 Strike: $15.44	$0.00	Disclosure SEC source: 0001672659-26-000008 · wk-form4_1768959233.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 416 shares Expires 2033-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
January 20, 2026 Filed Jan 21, 2026 01:33 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	416	$32.10	$13,353.60	Disclosure SEC source: 0001672659-26-000008 · wk-form4_1768959233.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
January 20, 2026 Filed Jan 21, 2026 01:33 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionCommon Stock	416	$15.44	$6,423.04	Disclosure SEC source: 0001672659-26-000008 · wk-form4_1768959233.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Read SEC document
January 14, 2026 Filed Jan 16, 2026 00:07 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	SaleCommon Stock	11,367	$32.61	$370,644.91	Disclosure SEC source: 0001672659-26-000006 · wk-form4_1768522053.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,437 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.99 to $32.91. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
January 13, 2026 Filed Jan 16, 2026 00:07 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	4,167	$0.00 Strike: $14.25	$0.00	Disclosure SEC source: 0001672659-26-000006 · wk-form4_1768522053.xml · derivative · entry 6 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,167 Underlying: Common Stock · 4,167 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document
January 13, 2026 Filed Jan 16, 2026 00:07 UTC	Mineralys Therapeutics, Inc. MLYS · Entity 4432	Exercise / conversionStock Option · Derivative	3,542	$0.00 Strike: $10.20	$0.00	Disclosure SEC source: 0001672659-26-000006 · wk-form4_1768522053.xml · derivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,042 Underlying: Common Stock · 3,542 shares Expires 2035-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F3 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.